Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model

Ann Oncol. 2019 Aug 1;30(8):1405. doi: 10.1093/annonc/mdy557.
No abstract available

Publication types

  • Published Erratum